Implantable cardioverter-defibrillators (ICDs) have mortality benefits over pharmacotherapy in patients with ventricular tachycardia (VT), ventricular fibrillation (VF), and sudden cardiac death without a reversible cause. This is true for both secondary prevention and primary prevention in certain high-risk patient groups. [1] [2] [3] Despite these advantages, shock therapies from ICDs are associated with significant psychological and physical morbidity, impaired quality of life, frequent hospital attendances, considerable health care costs, and, in the case of appropriate ICD shocks, increased mortality. [4] [5] [6] [7] [8] The number of ICD shock patients receive directly correlates with the number of hospitalizations and deaths, and the degree of psychological morbidity. 9, 10 More than 20% of ICD shocks are inappropriately triggered by supraventricular arrhythmias. 11 For these reasons, many patients require concomitant therapy with antiarrhythmic drugs to reduce the number of ICD shocks they receive.
Relatively few published trials have assessed the efficacy of adjuvant antiarrhythmic drug therapy in ICD patients, although the reduction in arrhythmic events and in ICD-delivered therapies is recognized as an important goal for these patients. No drug is specifically approved by the US Food and Drug Administration or outside the United States for adjuvant use in patients with ICD, and the drugs used currently have important disadvantages, mainly due to adverse effects and incomplete efficacy.
Azimilide is a novel, class III antiarrhythmic drug that blocks both the rapid (IKr) and slow (IKs) components of the delayed rectifier potassium current in the heart. 12 Animal studies have demonstrated that azimilide prolongs cardiac refractoriness 13 and lowers defibrillation thresholds.
14 A prior placebo-controlled outcomes study 15 in 3,717 high-risk cardiac patients demonstrated that therapy with azimilide did not negatively impact mortality, unlike many antiarrhythmic drugs. Further clinical studies, including the original SHIELD study, 16 showed that azimilide significantly reduces the number of appropriate shocks and antitachycardia pacing (ATP) episodes in patients with ICDs. 17 A further substudy of the SHIELD trial demonstrated a reduction in the number of hospital attendances in the azimilide arm. 5 The aim of this study was to further evaluate in detail the efficacy and safety of a 75-mg dose of azimilide daily, for use in patients with ICDs, especially in regard to hospitalizations and interventions. The 75-mg dose was chosen because the original SHIELD study demonstrated no significant incremental benefit in primary study end points when using a 125-mg dose of azimilide. The methodology was therefore deliberately designed to be similar to the previous substudy of SHIELD, 5 so as to provide comparable data for regulatory bodies to evaluate the drug for this adjuvant indication. We present the results of the randomized control trial, SHIELD-2, which was prematurely discontinued due to withdrawal of funding by the study sponsor. The study was curtailed due to a business decision that was made solely by the sponsor, blinded to study results, and not due to any study conduct issue, safety signal, or apparent absence of efficacy of the study drug.
Methods

Study design
This study was a randomized, double-blind, multicenter, placebo-controlled, parallel-group trial. Patients were randomized to receive up to 12 months of placebo or 75 mg of oral azimilide, once daily. Patients were followed up for an additional 30 days after the 12-month intervention period, or after premature discontinuation of the study drug. On-treatment follow-up was due to be stopped 6 months after the last patient was enrolled, and the study was due to be stopped when the last patient had completed a 30-day posttreatment visit. This study was conducted in accordance with guidance detailed in the Declaration of Helsinki.
Study population
Patients had to be at least 18 years old, with an ICD and a left ventricular ejection fraction (LVEF) of ≤40%. If the patient's ICD had been recently implanted, randomization needed to occur within 60 days of ICD implant and there was a required, documented episode of sustained VT, VF, or cardiac arrest in the 42-day period before the ICD insertion. Patients with an ICD implanted more than 60 days before enrollment were included if they had an ICD-delivered shock triggered by confirmed VT or VF and randomization could occur within 180 days of receiving this shock. All ICDs were required to have arrhythmia-discriminating algorithms (eg, high rate or sudden onset or rate stability).
Key exclusion criteria were the following: (1) New York Heart Association (NYHA) class IV congestive heart failure or decompensated congestive heart failure at randomization; (2) VF qualifying for ICD implantation or for study inclusion occurring within 48 hours of a myocardial infarction; (3) a history of torsade de pointes; (4) an electrocardiogram with a QTc N460 milliseconds and a QRS ≤120 milliseconds during screening; (5) an electrocardiogram with a JTc N340 milliseconds and a QRS N120 milliseconds during screening; (6) abnormalities in serum creatinine (N2.5 mg/dL [221 μmol/L]), liver function tests, potassium, or magnesium; (7) an absolute neutrophil count b1000/μL before randomization; (8) use, at the time of enrollment, of class I or III antiarrhythmic drug, QT-prolonging drugs, or immunemodulating drugs; and (9) amiodarone administered orally within 60 days before randomization or intravenously within 14 days before randomization. Patients with a serum creatinine qualifying for enrollment but with some renal insufficiency did not require dose adjustment of study drug.
Outcome assessments
The primary composite outcome was the time to first unplanned cardiovascular (CV) hospitalization, CV emergency department (ED) visit, or CV death. Secondary outcomes were the following: (1) time to first all-cause shock and (2) time to the first outpatient visit resulting in a change in ICD programming or to medication, as a result of ICD findings. The clinical events committee, who were blinded to treatment allocation and independent of study staff, adjudicated all events.
End point measurement
Patients had scheduled evaluations at screening; at baseline; at weeks 2, 4, 6, 8, and 10; at months 3, 6, 9, and 12; and at the withdrawal visit. At scheduled visits, patients were asked if they were hospitalized or had a visit to the ED or outpatients department. Implantable cardioverter-defibrillators were interrogated at the scheduled 3-, 6-, and 9-month visits; at the end of the study or upon withdrawal; and in the event of a protocol-defined primary or secondary outcome being reached. The ICD programming parameters used in the study are detailed in Appendix A.
Treatment duration
The planned duration of exposure to study drug was up to a maximum of 12 months, with shorter periods due to withdrawal from the study (eg, due to death and serious adverse event with clear causation from drug) or potentially for patients randomized during the last 6 months of enrollment. The latter design feature of the study was due to study termination which was planned to occur when the target number of primary outcome events had been accumulated, originally projected to occur approximately 6 months after last-patient enrollment.
Statistical methods
Sample size determination. This study had an event-driven design with the primary end point of clinical events committee-confirmed incidence of unplanned CV hospitalizations, unplanned CV ED visits, or CV death (event). Because the primary treatment comparisons in this study were based on time-to-event methodology using the log-rank test, or equivalently, the Cox proportional hazards model, the approach used for calculating sample size requirements for this study was based on the sample size methodology outlined in Schoenfeld. 18 For the primary outcome of the time to first unplanned CV hospitalization, CV ED visit, or CV death, a total of 388 primary events were calculated to be necessary to provide at least 90% power to detect a hazard ratio (HR) of 0.72. This was based on the assumptions of the following: a 50% 1-year event rate in the placebo group, a 36% event rate in the azimilide group, and a treatment exposure of 12 months. Based on a 12% dropout rate, the study therefore intended to enroll approximately 890 patients (445 patients per study arm) and would continue enrollment until at least 330 patients were observed to have at least one confirmed primary event, with the projection that after this enrollment cutoff, at least 388 primary events would occur before study completion.
Planned efficacy analyses. Primary and secondary outcomes were planned to be analyzed using the log-rank test or Cox proportional hazards model. Under the intention-to-treat principle, all randomized patients were planned to be included in this analysis and a censoring mechanism applied to those patients without an event for 365 days of study follow-up. The time to first event (unplanned CV hospitalizations, unplanned CV ED visits, or CV death) was planned to be calculated as (event date − randomization date + 1). Patients without an event at the end of day 365 of study follow-up would have their efficacy measure censored at day 365. Patients who withdrew from the study before completing 365 days of study follow-up and without experiencing an event would have time-to-event measures censored on their withdrawal date. Patients without an event and who were lost to follow-up were planned to be censored on the day of last contact. Every effort was made to encourage patient follow-up and for investigators to keep patients under study observation, even if they have experienced their primary end point.
The Cox proportional hazards model, with treatment (azimilide or placebo) represented by an indicator variable as a covariate, was intended to be used to obtain an estimate of the HR for the azimilide 75-mg group to the placebo group, with a 95% CI. In addition, the Cox proportional hazards model with treatment (azimilide or placebo) represented by an indicator variable and potential baseline variables as covariates (diabetes, age [b65 and ≥65 years], sex, history of myocardial infarction, ejection fraction [b30% and 30%-40%], and NYHA class) were intended to be used to estimate the adjusted HRs of the azimilide 75-mg group to the placebo group. A log-rank test was intended to assess the statistical significance of observed treatment differences in the time-to-event distributions between placebo and the azimilide groups. Differences in recurrent events between azimilide and placebo groups were planned to be collected and analyzed using the Andersen-Gill method.
Considerations upon study curtailment. After study curtailment, because of the resultant low sample size, we were unable to use the time-to-event methodology in the planned efficacy analyses described above. We instead presented results as numerical and percentage data. Odds ratios were used as a description of relative risk as we did not have enough data at various time points in the study to reliably report hazards ratios. Tests of statistical significance were not performed due to the lower number of outcome events than initially projected by power calculations. The trial did not last long enough to collect meaningful tertiary event data; therefore, no analyses on recurrent events between azimilide and placebo groups were possible.
Safety analyses. Data on safety assessments were tabulated and, as per prespecified plans, were not analyzed by statistical methods.
The SHIELD-2 study was funded by Forest Laboratories, LLC (Allergan plc).
Results
The study population was predominantly an older population of white men (89.6%) with a mean ± SD age of 65.5 ± 9.6 years and a mean ± SD LVEF of 29% ± 7%. Most patients had existing, rather than newly implanted ICDs (89.6%). Patient demographics and comorbidities were comparable between treatment groups and are summarized in Table I .
When the sponsor decided to stop funding the study, only 27 (11.3%) of the 240 patients randomized had fully completed the study; that, 27 patients either died or completed 12 months of intervention plus an additional 30 days of follow-up. The reasons why the remaining patients did not complete the study are outlined in Table II , the most common reason due to discontinuation of study funding (64.6%). The mean duration of exposure to azimilide and placebo was 144.7 vs 153.2 days, respectively. Patients with a QTc value N525 milliseconds (with a QRS ≤120 milliseconds) or a JTc value N400 milliseconds (with a QRS N120 milliseconds) were withdrawn from the study immediately. Patients with a QTc value N500 milliseconds (with a QRS ≤120 milliseconds) or a JTc value N380 milliseconds (with a QRS N120 milliseconds) could stay in the study, pending the results of electrolyte investigation and discussion between the investigator and medical monitor.
Primary and secondary outcomes
Azimilide, compared with placebo, numerically reduced the composite primary end point of the number of unplanned CV hospitalizations, or ED visits, or CV death. Azimilide also numerically reduced the secondary end point of all-cause shocks, but not the number of outpatient appointments resulting in a change in ICD programming or medication (Table III) . The primary and secondary outcome measures are also summarized in a forest plot in Figure 1 . Because of premature curtailment, the study is underpowered, likely contributing to relatively broad CIs.
Adverse events
Overall, fewer adverse events were observed in the azimilide group compared with the placebo group. A summary of the number of adverse events by category is shown in Table IV . Of note, there were no occurrences of neutropenia in the study population (absolute neutrophil count b1000 μ/L). There was one case of possible torsade de pointes in the azimilide group, which led to a successful ICD discharge. Twenty-one participants (17.5%) taking placebo and 16 (13.3%) participants taking azimilide discontinued their study medication due to an adverse event. The most Figure 1 Forest plot of the primary and secondary outcome measures. Points represent the odds ratio; bars represent ± 95% CI. common adverse events leading to study discontinuation in the azimilide group were VT (n = 6; 5%), cardiac failure (n = 2; 1.7%), and prolonged QTc/JTc interval (n = 2; 1.7%). There were no trends in the data suggesting any newly described adverse events related to azimilide therapy. Data for the noteworthy treatment-emergent adverse events are shown in detail in Appendix B.
Discussion
The main finding of the SHIELD-2 study is that in the limited data set available, the experimental class III antiarrhythmic azimilide numerically reduced the primary composite outcome of the number of unplanned CV hospitalizations, or ED visits, or CV death, compared with placebo. This corroborates the finding of a previous substudy 5 of SHIELD, in which azimilide significantly reduced the number of CV ED visits and hospitalizations compared with the placebo arm. 5 This finding has beneficial implications for ICD patients in terms of preventing physical and psychological morbidity as well as economic benefits for the health service and the general population.
The SHIELD-2 study also demonstrated a numerical reduction in the number of all-cause shocks in the azimilide arm. The original SHIELD study 16 showed a statistically significant reduction in the combined primary end point of all-cause shocks plus ATP therapies in azimilide compared with placebo, but the reduction in all-cause shocks as a single end point did not reach statistical significance. However, reduction in appropriate shocks was statistically significant in SHIELD. This may be because azimilide has not been shown to be markedly effective at preventing supraventricular arrhythmias 19, 20 and is therefore more likely to prevent appropriate, rather than inappropriate shocks. In addition, the number of shocks is not only determined by the number of arrhythmic events alone, but is also influenced by ICD programming. Differences in rate detection windows and the number and type of ATP trains between devices will influence the number of shocks fired regardless of the number or rate of any arrhythmias present. 16 Because a significant number of arrhythmias are slowed by the action of antiarrhythmic drugs and subsequently terminated by ATP, it may be most appropriate to measure the efficacy of adjuvant antiarrhythmic drugs in terms of their ability to decrease the number of shocks + ATP, rather than simply all-cause shocks. 17 The number of patients in our truncated study is too small to specifically evaluate the effect of azimilide on appropriate shocks, ATP, and inappropriate shocks; however, it is important to note that the ICD programming stipulated in the study protocol required the inclusion of a zone with ATP therapy and that site physicians were allowed to adapt contemporary programming approaches into patients' ICDs settings.
Taken as an individual outcome, there was no significant difference in the number of deaths between the azimilide or placebo arms in the SHIELD-2, SHIELD, or the pilot study of azimilide by Singer et al. 17 Although ICD shocks have previously been associated with an increased risk of mortality, our finding is not unexpected because ICD shocks may well be an adverse prognostic marker, rather than linked to mortality in a causal manner. Indeed, a systemic review of adjuvant therapies in ICD patients by Ha et al 21 found no evidence that reducing the number of ICD shocks significantly influences patient survival. Reassuringly, azimilide did not demonstrate an increase in mortality in either of the SHIELD studies or in a previous study of patients with recent myocardial infarction. 15 It is also reassuring that we found a lower number of adverse events in the azimilide arm. Importantly, there were no reported incidences of neutropenia in the study. Azimilide has previously been associated with a rare incidence (0.5%) of severe, but reversible neutropenia. 15, 16 Prior incidences of azimilide-associated neutropenia occurred in studies using higher doses of azimilide (100-125 mg). 16, 17 This may be a dose-dependent effect not seen at the 75-mg dose used in SHIELD-2. Azimilide has previously been shown to have a 1% incidence of torsade de pointes in a combined review of previous trials 22 and in the SHIELD study. In SHIELD-2, there was one possible case of torsade de pointes in the azimilide arm, which led to a successful ICD discharge. The rate of torsade de pointes seen with azimilide is fairly low compared with other antiarrhythmic drugs currently used and is of less concern in patients who have an ICD and/or pacing support.
Conclusion
There is an unmet clinical need to find an adjuvant therapy for ICD patients, which can suppress arrhythmias capable of triggering appropriate and inappropriate ICD shocks. The SHIELD-2 trial was statistically underpowered due to early trial termination and did not meet its primary objective. Despite this limitation, azimilide, a class III antiarrhythmic drug, showed promise in this study as a safe and effective drug for potentially reducing the number of shocks, unplanned hospitalizations, and ED visits in ICD patients. These data support prior clinical trial findings with this drug including the SHIELD study. 
